PMID 11498540
Think Youve Found What Youre Looking For
Several trials with tirzepatide are also ongoing, including SURPASS-6, SURPASS-J, SURPASS-AP, and SURPASS-CVOT, all of which will look at the effects of this agent compared to other agents (insulin lispro, dulaglutide, insulin glargine) on weight, HbA1c, and the occurrence of major adverse cardiovascular events (MACE), respectively [38]
While the weight-loss data for semaglutide are encouraging, to really get the cardiologists excited about prevention and weight loss, especially addressing weight loss in the context of a cardiovascular visit, what is needed are CV outcomes trials that show meaningful outcomes differences, Neeland said in an interview